Altough further understanding of the other possible mechanisms involved in the apparent specific anti-apoA-1 IgG cytotoxicity on tumoral cells is required, the present results may open new therapeutic perspectives, especially in brain tumors, where an intrathecal infusion of these antibodies could be envisaged in top of other systemic chemotherapy agents. The gene discussed is APOA1; the disease is brain neoplasm.